Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419649 · ClinicalTrials.gov registry record · Phase 2
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
A Phase 2 study of Myelodysplastic Syndromes and Cytopenia, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT04419649 is a Phase 2 study of Myelodysplastic Syndromes and Cytopenia that is actively recruiting participants, run by Takeda. The registered enrollment target is 160 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04419649, a Phase 2 study of Myelodysplastic Syndromes and Cytopenia, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.
Conditions Studied
Interventions
- DRUG Elritercept
Study Locations (20)
Victoria
- Boxhill Hospital - Box Hill
- University Hospital Geelong - Geelong
- Austin Health - Heidelberg
- Royal Melbourne Hospital - Melbourne
- St Vincent's Hospital Melbourne - Melbourne
- Ballarat Oncology & Haematology Service - Wendouree
New South Wales
- Border Medical Oncology Research - Albury
- Tweed Hospital - Tweed Heads
- Westmead Hospital - Westmead
Other
- Fakultni nemocnice Brno - Brno
- Fakultni nemocnice Kralovske Vinohrady - Prague
- Vseobecna Fakultni Nemocnice Praha - Prague
Florida
- University of Miami School of Medicine Sylvester Comprehensive Cancer Center (SCCC) - Miami
- H. Lee Moffitt Cancer Center and Research Center - Tampa
South Australia
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford Park
California
- City of Hope National Medical Center - Duarte
Michigan
- Karmanos Cancer Institute at Mclaren Greater Lansing - Lansing
Pennsylvania
- University of Pittsburgh Medical Health Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2031-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419649
The ClinicalTrials.gov registry entry for NCT04419649 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (44% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Elritercept is the first listed.
NCT04419649 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Victoria, New South Wales, Other.
Frequently Asked Questions
What is clinical trial NCT04419649 about?
NCT04419649 is a clinical study titled "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)". The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the s...
What is the current status of trial NCT04419649?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2020-08-19. Estimated completion is 2031-10-30.
What conditions does trial NCT04419649 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Cytopenia.
What interventions are being tested in trial NCT04419649?
The interventions under investigation include: Elritercept (DRUG).
Who is sponsoring clinical trial NCT04419649?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04419649 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.